Back to Search Start Over

Current status of immunodeficient mouse models as substitutes to reduce cat and dog use in heartworm preclinical research.

Authors :
Dagley JL
DiCosty U
Fricks C
Mansour A
McCall S
McCall JW
Taylor MJ
Turner JD
Source :
F1000Research [F1000Res] 2024 Sep 11; Vol. 13, pp. 484. Date of Electronic Publication: 2024 Sep 11 (Print Publication: 2024).
Publication Year :
2024

Abstract

Chemoprophylactic prevention of veterinary heartworm disease in companion animals, caused by the vector-borne nematode parasite Dirofilaria immitis, is a multi-billion-dollar global market. Experimental use of cats and dogs in preclinical heartworm drug testing is increasing due to evolving drug-resistance to frontline macrocyclic lactones and renewed investment in alternative preventative drug research. We and others recently published data demonstrating proof-of-concept of utilising lymphopenic severe-combined immunodeficient (SCID) or Recombination Activating Gene (RAG)2 deficient mice with additional knockout of the IL-2/7 receptor gamma chain (γc) as alternative preventative drug screening research models of dirofilariasis. Here we summarise the current knowledge of candidate immunodeficient mouse models tested, including a comparison of susceptibility using different background strains of mice, different D. immitis isolates, following use of anti-inflammatory treatments to further suppress residual innate immunity, and efficacies achieved against different reference anthelmintics. We supplement this precis with new data on treatment response to the veterinary anthelmintic, oxfendazole, and initial evaluation of D. immitis susceptibility in CB.17 SCID and C57BL/6 RAG2 <superscript>-/-</superscript> γc <superscript>-/-</superscript> mice. We conclude that in addition to NSG and NXG mice, RAG2 <superscript>-/-</superscript> γc <superscript>-/-</superscript> mice on either a BALB/c or C57BL/6 background offer an alternative screening model option, widening access to academic and commercial laboratories wishing to pursue initial rapid in vivo drug screening whilst avoiding potentially unnecessary cat or dog testing.<br />Competing Interests: Competing interests: CF, UD, AM, SM, and JM are employed by TRS Laboratories Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright: © 2024 Dagley JL et al.)

Details

Language :
English
ISSN :
2046-1402
Volume :
13
Database :
MEDLINE
Journal :
F1000Research
Publication Type :
Academic Journal
Accession number :
39036651
Full Text :
https://doi.org/10.12688/f1000research.149854.2